HROW
A little more confidence, finally
Harrow just got an upgrade from Hold to a cautious Buy, and the pitch is pretty simple: Q2 looked better, and the business is starting to show more of that elusive thing investors love to chase — operating leverage. In plain English, the company may finally be turning more of its sales growth into actual profit-ish momentum.
Why the market might care
The analyst pointed to improved revenue and economics for VEVYE, plus record demand for IHEEZO even with reimbursement headwinds still hanging around like that one relative who won’t leave Thanksgiving early. That combo makes the growth story look sturdier than before, which matters when you're trying to justify a higher multiple.
The math behind the mood shift
The model now calls for:
- about $490 million in 2027 revenue
- a 4.5x EV/sales multiple
- a $52 price target
That target implies roughly 33% upside from current levels, which is a nice way of saying the stock doesn’t need a miracle — just continued execution.
Big picture
This isn’t a loud, moonshot-style call. It’s a cautious nudge that says, “Hey, maybe the turnaround is real.” For investors, that can be enough to keep the name interesting if the next few quarters keep trending the right way.